Key points from article :
MitoRx Therapeutics aims to reverse mitochondrial dysfunction to halt progression of degenerative disease.
Secured seed funding to develop its mitochondrial-protective therapeutics.
Funds towards its pre-clinical proof-of-concept platform, research collaborations and partnerships.
According to Pitchbook, the company has raised around $2.1 million to date.
Complete reversal of loss-of strength in a C. elegans model of Duchenne muscular dystrophy.
Neuroprotection in a mammalian model of Alzheimer’s disease, through the restoration of sulphide-signalling.
Therapeutic pipeline of small molecule candidates for Duchenne muscular dystrophy (DMD), CBS-deficiency, and Huntington’s disease.
The company also claims to have programs in Alzheimer’s, Parkinson’s, sarcopenia, cancer cachexia, COPD and IPF.
“We are the first biotech to address dysfunction of sulphide-signalling, a fundamental part of life’s energy systems,” - Jon Rees, CEO of MitoRx.
